1-2 of 2
Ioanna Dialoupi
Close
Sort by
Journal Articles

Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone

Clinical Trials & Observations
Efstathios Kastritis, Maria Roussou, Maria Gavriatopoulou, Nikolaos Kanellias, Magdalini Migkou, Evangelos Eleutherakis-Papaiakovou, Dimitrios C. Ziogas, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Ioanna Dialoupi, Stavroula Giannouli, Panagiotis Tsirigotis, Sossana Delimpasi, Despina Mparmparousi, Mairylin Spyropoulou-Vlachou, Aikaterini Xirokosta, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2019) 3 (23): 4095–4103.
https://doi.org/10.1182/bloodadvances.2019000539
Published: 2019
Journal Articles

Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone

Efstathios Kastritis, Ioanna Dialoupi, Maria Gavriatopoulou, Maria Roussou, Nikolaos Kanellias, Despina Fotiou, Ioannis Ntanasis-Stathopoulos, Elektra Papadopoulou, Dimitrios C. Ziogas, Kimon Stamatelopoulos, Efstathios Manios, Argyrios Ntalianis, Evangelos Eleutherakis-Papaiakovou, Asimina Papanikolaou, Magdalini Migkou, Aristea-Maria Papanota, Harikleia Gakiopoulou, Erasmia Psimenou, Maria Irini Tselegkidi, Ourania Tsitsilonis, Ioannis Kostopoulos, Evangelos Terpos, Meletios A. Dimopoulos
Journal: Blood Advances
Blood Adv (2019) 3 (20): 3002–3009.
https://doi.org/10.1182/bloodadvances.2019000147
Published: 2019
Includes: Supplemental data